Biomea Fusion (NASDAQ:BMEA) Earns Buy Rating from D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Free Report) in a report issued on ...
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be presented at ...
Biomea Fusion to become diabetes, obesity medicines company
Biomea Fusion (BMEA) announced the company will become a diabetes and obesity medicines company. Based on the most recent clinical trial ...
Biomea Fusion price target lowered to $16 from $128 at D. Boral Capital
D. Boral Capital lowered the firm’s price target on Biomea Fusion (BMEA) to $16 from $128 and keeps a Buy rating on the shares. The company ...
Morningstar10d
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical ...
manilatimes11d
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Icovamenib, a potential first-in-class menin inhibitor for the treatment of diabetes, demonstrated the strongest activity in patients with the lowest insulin production Placebo adjusted 1.5% mean ...
Mena FN10d
Biomea Fusion To Become A Diabetes & Obesity Medicines Company
2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or“Biomea ...
Stockhouse10d
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the ...